Friday, July 10, 2026

Drug profile · INN

duloxetine hydrochloride 20 mg oral capsule, delayed release

duloxetine hydrochloride 20 mg oral capsule, delayed release is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — duloxetine hydrochloride 20 mg oral capsule, delayed release
Class
Route
Patents
0
Programs
5
Data quality
0.70

Quick answer

duloxetine hydrochloride 20 mg oral capsule, delayed release is an FDA-listed pharmaceutical active ingredient.

Key facts

INN duloxetine hydrochloride 20 mg oral capsule, delayed release

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. Delayed and extended release mesalazine Phase 3 · Takeda · Colitis, Ulcerative
  2. Delayed Release 6 mercaptopurine Phase 2 · Teva Pharma · Crohn's Disease
  3. Delayed Release 6MP or Calcitriol vs. Purinethol Phase 2 · Teva Pharma · Crohn's Disease
  4. DELAY Phase 1 · George Institute for · Lynch Syndrome
  5. Delayed Release 6 mercaptopurine Phase 1 · Teva Pharma · Crohns Disease

Frequently asked questions

What is duloxetine hydrochloride 20 mg oral capsule, delayed release?

duloxetine hydrochloride 20 mg oral capsule, delayed release is an FDA-listed pharmaceutical active ingredient.